Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antibiotic help the brain heal after a stroke?

NCT ID NCT07338175

Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the antibiotic minocycline can help people recover better after a spontaneous brain bleed (intracerebral hemorrhage). About 1,200 adults who had a bleed within the last 48 hours will receive either minocycline or a placebo for a short time. The goal is to see if the drug reduces long-term disability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 1,192 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. CT-confirmed spontaneous supratentorial intracerebral hemorrhage; 2. Aged 18 to 80 years; 3. Within 48 hours of symptom onset; 4. Hematoma volume 15-40 ml; 5. NIHSS score 8-24, with item 1a ≤ 2; 6. Signed informed consent by the patient or legal representative. Exclusion Criteria: 1. Secondary intracerebral hemorrhage (traumatic, tumor-related, vascular malformation, aneurysm, coagulation disorder, etc.); 2. Intraventricular hemorrhage filling one entire lateral ventricle, third ventricle, or fourth ventricle, or more than half of two lateral ventricles; 3. Significant subarachnoid hemorrhage (Fisher grade ≥ 3) or subdural hemorrhage; 4. Patients with uncontrollable hypertension ( systolic blood pressure persistently ≥ 180 mmHg despite intensive antihypertensive treatment); 5. Progressive neurological or other severe systemic diseases; 6. Planned surgical intervention for the intracerebral hemorrhage; 7. Pre-stroke disability (modified Rankin Scale score \> 1); 8. Severe cardiac insufficiency (NYHA Class III-IV), severe liver disease (ALT or AST \> 3 times the normal upper limit value), severe renal insufficiency (serum creatinine \> 2 times the normal upper limit value, or glomerular filtration rate \< 45 ml/min), or malignancy with life expectancy \< 1 year; 9. Moderate to severe anemia (hemoglobin \< 90 g/L), thrombocytopenia (platelet count \< 100×10\^9/L), leukopenia (white blood cell count \< 2×10\^9/L), or coagulopathy (INR \> 1.5); 10. Allergy or intolerance to minocycline or other tetracycline antibiotics; 11. History of pseudomembranous enteritis or antibiotic-associated enteritis; 12. Use of tetracycline antibiotics within the past week; 13. Intracranial or spinal surgery within the past 3 months; 14. Any major surgery or severe physical trauma within the past month; 15. Females who are pregnant, within 30 days postpartum, or in the lactation period. 16. Participated in other interventional clinical trials within the past 3 months; 17. Inability to obtain signed informed consent from the patient or representative; 18. Other conditions that are not suitable for participating in this clinical trial, such as inability to understand and/or follow the research procedures due to mental, cognitive, emotional, or physical disorders, etc.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intracerebral hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cyclopia sequence intracerebral hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intracerebral hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    41 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • [email protected]

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Affiliated Hospital of Nantong University

    RECRUITING

    Nantong, Jiangsu, China

  • Baoding Fourth Central Hospital (Tangxian, Hebei)

    RECRUITING

    Baoding, Hebei, China

  • Baotou Central Hospital

    RECRUITING

    Baotou, Inner Mongolia, China

  • Beijing Tiantan Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Binzhou Central Hospital, Shandong Province

    RECRUITING

    Binzhou, Shandong, China

  • Chongqing Tongnan District People's Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • Dalian Lushunkou District Hospital of Traditional Chinese Medicine

    RECRUITING

    Dalian, Liaoning, China

  • General Hospital of Pingmei Shenma Medical Group

    RECRUITING

    Pingdingshan, Henan, China

  • Henan Sanbo Brain Hospital

    RECRUITING

    Zhengzhou, Henan, China

  • Kuandian Central Hospital

    RECRUITING

    Dandong, Liaoning, China

  • Liuyang Jili Hospital

    RECRUITING

    Guankou, Hunan, China

  • Mengzhou Fuxing Hospital

    RECRUITING

    Mengzhou, Henan, China

  • Nanle County People's Hospital

    RECRUITING

    Nanle, Henan, China

  • Neixiang County People's Hospital

    RECRUITING

    Neixiang, Henan, China

  • Ningbo Second Hospital

    RECRUITING

    Ningbo, Zhejiang, China

  • Ordos Central Hospital

    RECRUITING

    Ordos, Inner Mongolia, China

  • People's Hospital of Inner Mongolia Autonomous Region

    RECRUITING

    Hohhot, Inner Mongolia, China

  • Puyang County People's Hospital

    RECRUITING

    Puyang, Henan, China

  • Shangqiu Third People's Hospital

    RECRUITING

    Shangqiu, Henan, China

  • Shaodong People's Hospital

    RECRUITING

    Shaodong, Hunan, China

  • Siyang Kangda Hospital

    RECRUITING

    Siyang, Jiangsu, China

  • Suixian Hospital of Traditional Chinese Medicine

    RECRUITING

    Shangqiu, Henan, China

  • Taihe Hospital of Shiyan

    RECRUITING

    Shiyan, Hubei, China

  • Taikang County People's Hospital

    RECRUITING

    Taikang Chengguanzhen, Henan, China

  • The Fifth People's Hospital of Ningxia Hui Autonomous Region

    RECRUITING

    Shizuishan, Ningxia, China

  • The Second People's Hospital of Guangdong Province

    RECRUITING

    Guangzhou, Guangdong, China

  • Third People's Hospital of Liaocheng City, Shandong Province

    RECRUITING

    Liaocheng, Shandong, China

  • Tianjin Huanhu Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

  • Ulanqab Central Hospital

    RECRUITING

    Ulanqab, Inner Mongolia, China

  • Weihai Municipal Hospital

    RECRUITING

    Weihai, Shandong, China

  • Weihai Municipal Third Hospital

    RECRUITING

    Weihai, Shandong, China

  • Weihai Wendeng District People's Hospital

    RECRUITING

    Tianfu, Shandong, China

  • Wuyuan County People's Hospital

    RECRUITING

    Wuyuan, Inner Mongolia, China

  • Xianyang Hospital of Yan'an University

    RECRUITING

    Xianyang, Shaanxi, China

  • Yellow River Sanmenxia Hospital

    RECRUITING

    Sanmenxia, Henan, China

  • Yilong County People's Hospital

    RECRUITING

    Jincheng, Sichuan, China

  • Yingkou Fangda Hospital

    RECRUITING

    Yingkou, Liaoning, China

  • Yiyang Central Hospital

    RECRUITING

    Hunan, Yiyang, China

  • Zhangjiakou First Hospital

    NOT_YET_RECRUITING

    Zhangjiakou, Hebei, China

  • Zunhua People's Hospital

    RECRUITING

    Zunhua, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.